Turner Investments’s Travere Therapeutics TVTX Stock Holding History

Turner Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-43,754	Closed	-$828K	–	271
2016 Q4	$828K	Sell	43,754 -7,230	-14%	-$148K	0.33%	112
2016 Q3	$1.14M	Sell	50,984 -39,370	-44%	-$749K	0.38%	88
2016 Q2	$1.61M	Sell	90,354 -52,510	-37%	-$850K	0.5%	63
2016 Q1	$1.95M	Sell	142,864 -241,896	-63%	-$3.67M	0.53%	64
2015 Q4	$7.42M	Buy	384,760 +146,720	+62%	+$2.93M	1.54%	8
2015 Q3	$4.82M	Buy	238,040 +94,800	+66%	+$2.81M	0.98%	32
2015 Q2	$4.75M	Sell	143,240 -26,740	-16%	-$732K	0.87%	29
2015 Q1	$4.07M	Sell	169,980 -59,600	-26%	-$909K	0.73%	40
2014 Q4	$2.81M	Sell	229,580 -111,920	-33%	-$1.16M	0.33%	79
2014 Q3	$3.08M	Buy	+341,500	New	+$4.02M	0.18%	162

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Turner Investments's TVTX Position: Q1 2017 in Review

Turner Investments sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 43,754 shares — an estimated $828K sold.

Turner Investments first reported a position in TVTX in Q3 2014 and held it in 10 quarters. The position peaked at $7.42M in Q4 2015. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

Turner Investments reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
Turner Investments sold 43,754 Travere Therapeutics shares in Q1 2017, an estimated $828K.
Turner Investments first reported a position in Travere Therapeutics in Q3 2014 and held it in 10 quarters.
Turner Investments's Travere Therapeutics position peaked at $7.42M in Q4 2015.
114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.